Skip to main content

You must have JavaScript enabled in order to access this part of the site. Please enable JavaScript and then reload this page in order to continue.

COVID-19 Drug Veklury (Remdesivir) Update

Last updated on

Beginning April 25, 2022, Veklury (J0248) is an approved benefit for Medicaid and Children’s Health Insurance Program (CHIP) clients 28 days or older when used in an outpatient setting. Previously, the Texas Health and Human Services Commission (HHSC) approved Veklury (remdesivir lyophilized injection) for clients 12 years or older.

On April 25, 2022, the U.S. Food and Drug Administration (FDA) expanded the use of Veklury (remdesivir lyophilized injection) for patients in the outpatient setting. Veklury is indicated for clients meeting all the following criteria:

  • Age 28 days or older
  • Weighing at least 3 kg
  • Having mild to moderate COVID-19
  • Are at high risk for progression to severe COVID-19, including hospitalization or death


Providers can refer to the following resources for additional information:

Email comments or questions to